27907099|t|Analysis of a Mouse Skin Model of Tuberous Sclerosis Complex
27907099|a|Tuberous Sclerosis Complex (TSC) is an autosomal dominant tumor suppressor gene syndrome in which patients develop several types of tumors, including facial angiofibroma, subungual fibroma, Shagreen patch, angiomyolipomas, and lymphangioleiomyomatosis. It is due to inactivating mutations in TSC1 or TSC2. We sought to generate a mouse model of one or more of these tumor types by targeting deletion of the Tsc1 gene to fibroblasts using the Fsp-Cre allele. Mutant, Tsc1ccFsp-Cre+ mice survived a median of nearly a year, and developed tumors in multiple sites but did not develop angiomyolipoma or lymphangioleiomyomatosis. They did develop a prominent skin phenotype with marked thickening of the dermis with accumulation of mast cells, that was minimally responsive to systemic rapamycin therapy, and was quite different from the pathology seen in human TSC skin lesions. Recombination and loss of Tsc1 was demonstrated in skin fibroblasts in vivo and in cultured skin fibroblasts. Loss of Tsc1 in fibroblasts in mice does not lead to a model of angiomyolipoma or lymphangioleiomyomatosis.
27907099	14	24	Mouse Skin	T024	C1519352
27907099	25	30	Model	T050	C2986594
27907099	34	60	Tuberous Sclerosis Complex	T191	C0041341
27907099	61	87	Tuberous Sclerosis Complex	T191	C0041341
27907099	89	92	TSC	T191	C0041341
27907099	100	109	autosomal	T026	C0596142
27907099	110	118	dominant	T169	C1527180
27907099	119	140	tumor suppressor gene	T028	C0079427
27907099	141	149	syndrome	T047	C0039082
27907099	159	167	patients	T101	C0030705
27907099	193	199	tumors	T191	C0027651
27907099	211	230	facial angiofibroma	T191	C0265319
27907099	232	249	subungual fibroma	T191	C0266003
27907099	251	265	Shagreen patch	T019	C0432363
27907099	267	282	angiomyolipomas	T191	C0206633
27907099	288	312	lymphangioleiomyomatosis	T191	C0751674
27907099	327	339	inactivating	T169	C0544461
27907099	340	349	mutations	T045	C0596611
27907099	353	357	TSC1	T028	C0694894
27907099	361	365	TSC2	T028	C0694895
27907099	391	402	mouse model	T050	C2986594
27907099	427	432	tumor	T191	C0027651
27907099	452	460	deletion	T045	C0017260
27907099	468	477	Tsc1 gene	T028	C0694894
27907099	481	492	fibroblasts	T025	C0016030
27907099	503	510	Fsp-Cre	T028	C1511573
27907099	511	517	allele	T028	C0002085
27907099	519	525	Mutant	T028	C0678941
27907099	527	541	Tsc1ccFsp-Cre+	T028	C0678941
27907099	542	546	mice	T015	C0025929
27907099	558	564	median	T081	C0876920
27907099	597	603	tumors	T191	C0027651
27907099	607	615	multiple	T081	C0439064
27907099	616	621	sites	T082	C0205145
27907099	626	641	did not develop	T033	C1513916
27907099	642	656	angiomyolipoma	T191	C0206633
27907099	660	684	lymphangioleiomyomatosis	T191	C0751674
27907099	715	719	skin	T022	C1123023
27907099	720	729	phenotype	T032	C0031437
27907099	742	752	thickening	T033	C0205400
27907099	760	766	dermis	T024	C0011646
27907099	772	784	accumulation	T033	C4055506
27907099	788	798	mast cells	T025	C0024880
27907099	809	818	minimally	T080	C0547040
27907099	819	829	responsive	T169	C0205342
27907099	833	841	systemic	T169	C0205373
27907099	842	851	rapamycin	T109,T195	C0072980
27907099	852	859	therapy	T061	C0087111
27907099	875	884	different	T080	C1705242
27907099	894	903	pathology	T046	C0677042
27907099	912	917	human	T016	C0086418
27907099	918	921	TSC	T191	C0041341
27907099	922	934	skin lesions	T047	C0037284
27907099	936	949	Recombination	T045	C0034865
27907099	954	958	loss	T081	C1517945
27907099	962	966	Tsc1	T028	C0694894
27907099	987	1003	skin fibroblasts	T025	C1272578
27907099	1004	1011	in vivo	T082	C1515655
27907099	1019	1027	cultured	T025	C0007600
27907099	1028	1044	skin fibroblasts	T025	C1272578
27907099	1046	1050	Loss	T081	C1517945
27907099	1054	1058	Tsc1	T028	C0694894
27907099	1062	1073	fibroblasts	T025	C0016030
27907099	1077	1081	mice	T015	C0025929
27907099	1082	1095	does not lead	T033	C1513916
27907099	1101	1106	model	T050	C2986594
27907099	1110	1124	angiomyolipoma	T191	C0206633
27907099	1128	1152	lymphangioleiomyomatosis	T191	C0751674